

# The Changing Treatment Paradigm After Progression in Advanced *EGFR*-Mutated NSCLC

Join us for the satellite symposium  
in Vienna on 5 December, 2016

07:30 – 08:30

**Room: Stolz 2**

Messe Wien Exhibition & Congress Center

Messeplatz 1

A-1021 Vienna – Austria

Expert perspectives from:



**Moderator**

**James Chih-Hsin Yang, MD, PhD**

Graduate Institute of Oncology  
National Taiwan University  
National Taiwan University Hospital  
Taipei, Taiwan



**Faculty**

**Anders Mellempgaard, MD, PhD**

Copenhagen University Hospital  
Herlev, Denmark



**Faculty**


**Howard West, MD**

Swedish Cancer Institute  
Global Resource for Advancing  
Cancer Education (GRACE)  
Seattle, Washington, USA

# The Changing Treatment Paradigm After Progression in Advanced *EGFR*-Mutated NSCLC

## AGENDA

- **Introduction: The Path Forward in Advanced *EGFR*-Mutated NSCLC**
- **Emerging Algorithm for Advanced *EGFR*-Mutated NSCLC After Progression**
- **Best Practices for Managing Advanced *EGFR*-Mutated NSCLC After Progression**
- **Panel Discussion: Overcoming Obstacles Managing Advanced *EGFR*-Mutated NSCLC After Progression**
- **Conclusions and Questions**



This activity is supported by an educational funding donation provided by AstraZeneca. This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice. Please contact [webmaster@pearcme.com](mailto:webmaster@pearcme.com) for more information.